Health Canada approved JERAYGO (aprocitentan) for resistant hypertension at a 12.5 mg once-daily dose, up-titrated to 25 mg as the first endothelin receptor antagonist for patients uncontrolled on ≥3 antihypertensives. In the 730-patient Phase 3 PRECISION trial, both 12.5 mg and 25 mg doses delivered rapid, durable double-digit systolic blood pressure reductions over 40 weeks.